Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib in MET ex14 NSCLC with Brain Metastases
NCT04460729Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
A Phase 2 trial of capmatinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Planned start Nov 2020; status: withdrawn.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04460729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460729.